Citable segment mix
VTRS's latest SEC segment disclosure for revenue by product shows Brands as the largest listed segment at $1.07B (30.4% of disclosed segment revenue).
| Segment | Period | Revenue | Mix |
|---|---|---|---|
| Brands | Mar 31, 2026 | $1.07B | 30.4% |
| Generics | Mar 31, 2026 | $951.80M | 27.1% |
| Lipitor ® | Mar 31, 2026 | $462.00M | 13.1% |
| Norvasc ® | Mar 31, 2026 | $210.00M | 6.0% |
| Lyrica ® | Mar 31, 2026 | $120.60M | 3.4% |
| EpiPen® Auto-Injectors | Mar 31, 2026 | $101.10M | 2.9% |
Source: SEC EDGAR segment disclosures; period Mar 31, 2026.
Continue research
Follow same-sector companies and source explainers connected to the segments view.
A factual guide to revenue segment disclosures and how Aerarium Research uses them to make company business mix easier to inspect.
A factual guide to seasonal revenue patterns and comparable (same-store) sales — why year-over-year comparisons matter and what comp sales strip out.
A factual guide to deferred revenue, cash collected before revenue is earned, and why the liability can matter for recurring businesses.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
